CR5.F CARDERO RESOURCE

Healthcare Metals & Mining Frankfurt Exchange
6.74 EUR
Close of Nov 12, 2026
5.80 29.30
Market cap
EUR 376M
P/E
-
P/B
1.65x
ROE
-36.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CR5.F undervalued?

Graham number

The Graham number of CARDERO RESOURCE cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CARDERO RESOURCE fundamental analysis

No fundamental analysis for CARDERO RESOURCE yet.

CARDERO RESOURCE stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CARDERO RESOURCE

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; an…

Full company profile